Fundamental Analysis of Bellerophon Therapeutics Inc - Growth / Value Index


BLPH - Valuation Highlights

Valuation Analysis

   Tsr Value Index - Very Poor Score of 5.00
   Price to Book Ratio of 28.86 suggesting that it is very expensive
   Book Value in last 3 years is trending down
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning 79.36 %
Price to Book 28.86 0 0 % 0.185
Price to Sales 30.61 0 0 %
Enterprise Value to EBITDA Multiple -0.0296 0 0 %


BLPH - Profitability Highlights

Profitability Analysis

   During the past twelve months, the company has given a strong Return On Equity of 36.36%
   During the past twelve months, the company has given a strong Return On Asset of 20.62%
   During the past twelve months, the company has given a strong Net Margin of 38.56%
   Annual Net Profit in last 3 years is trending up
   EBITDA is continuously increasing for last 3 Years
   Tsr Profitability Index - Poor Score of 29.46
   Piotroski F Score - Very Poor Value of 2.0
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   In the last three years, the company has given poor Net Margin
   In the last three years, the company has given poor Returns on Assets
   EPS decline for last four quarters
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity 36.36 % -51.60
Return On Asset 20.62 0 0 % -38.58
Net Profit Margin 38.56 -164.06 53.34 % 0
Operating Profit Margin -411.67 -195.67 50.70 % 0
EBITDA Margin -412.04 -163.95 58.69 % 0


Highlights
Market Cap688695
Enterprise Value688695
Price/Book TTM28.86
Outstanding Share12232.60 K
Float/ Outstanding Share83.41%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No
Peter Lynch Ratio0
Piotroski F Score2.00
Altman Z Score
Sloan Ratio
Peter Lynch Fair Value0.0139


BLPH - Growth Highlights

Growth Analysis

   Annual sales of the company is increased for three years in a row
   Tsr Growth Index - Very Poor Score of 11.54
   Quarterly sales in last 5 Quarter is trending down
   Company's Total Assets is Decreasing for last 3 years
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 5640.00 K 0 % %
Gross Profit 5640.00 K % %
EBITDA -23239.00 K 58.69 % 58.74 %
Net Profit 2175.00 K 53.34 % 62.61 %
EPS 0.0007 100.00 % NA


BLPH - Stability Highlights

Stability Analysis

   Tsr Stability Index - Excellent Score of 95.00
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of 0
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0 0 % 0
Cash Ratio 0 0 %
Quick Ratio 0 0 % 3.96
Shareholders Equity 0 0 %
Debt to EBITDA 0 0 %


Historical Valuation Ratios of Bellerophon Therapeutics Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Bellerophon Therapeutics Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Bellerophon Therapeutics Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Bellerophon Therapeutics Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)